Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials.
暂无分享,去创建一个
L. Leibovici | D. Yahav | A. Fraser | M. Paul
[1] Douglas G. Altman,et al. Systematic reviews in health care : meta-analysis in context , 2008 .
[2] L. Leibovici,et al. Single‐agent antibiotic therapy for the initial, empirical, treatment of febrile neutropenia: comparison of beta‐lactams , 2005 .
[3] H. Döhner,et al. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] L. Leibovici,et al. Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. , 2005, The Journal of antimicrobial chemotherapy.
[5] K. Rolston. Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] B. Psaty,et al. COX-2 inhibitors--lessons in drug safety. , 2005, The New England journal of medicine.
[7] G. Jacoby,et al. The new beta-lactamases. , 2005, The New England journal of medicine.
[8] G. Jacoby,et al. Mechanisms of disease: The new β-lactamases , 2005 .
[9] M. Egger,et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis , 2004, The Lancet.
[10] J. Mensa,et al. Prospective evaluation of procalcitonin in adults with febrile neutropenia after haematopoietic stem cell transplantation , 2004, British journal of haematology.
[11] P. Johansson,et al. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies , 2004, Scandinavian journal of infectious diseases.
[12] G. Kanra,et al. Cefepime vs. Meropenem as empirical therapy for neutropenic fever in children with lymphoma and solid tumours , 2004, Pediatric blood & cancer.
[13] J. Tarrand,et al. Current spectrum of bacterial infections in patients with cancer. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] L. Leibovici,et al. Considering resistance in systematic reviews of antibiotic treatment. , 2003, The Journal of antimicrobial chemotherapy.
[15] Ronald N. Jones,et al. Comparative activity and spectrum of broad-spectrum beta-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program (North America: 2001-2002). , 2003, Diagnostic microbiology and infectious disease.
[16] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[17] H. Kantarjian,et al. Treatment of febrile neutropenic patients with cancer who require hospitalization , 2003, Cancer.
[18] L. Leibovici,et al. β lactam monotherapy versus β lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis , 2003, BMJ : British Medical Journal.
[19] R. Wenzel,et al. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] G. Bodey,et al. Ciprofloxacin versus Tobramycin for Neutropenic Fevers , 2003, Annals of Internal Medicine.
[21] F. Goldstein. Cephalosporinase induction and cephalosporin resistance: a longstanding misinterpretation. , 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[22] S. Hanada,et al. Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th‐generation cephalosporin + aminoglycosides: Comparative study , 2002, American journal of hematology.
[23] T. Calandra,et al. Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer , 2002 .
[24] Chao‐Ping Yang,et al. Cefepime versus ceftazidime as empiric monotherapy for fever and neutropenia in children with cancer , 2002, The Pediatric infectious disease journal.
[25] F. Mandelli,et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] A. Simon,et al. Meropenem versus ceftazidime as empirical monotherapy in febrile neutropenia of paediatric patients with cancer. , 2001, The Journal of antimicrobial chemotherapy.
[27] R. Kebudi,et al. Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors. , 2001, Medical and pediatric oncology.
[28] M. Mustafa,et al. Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia , 2001, The Pediatric infectious disease journal.
[29] R. Ramphal,et al. Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[30] S. Cantor,et al. Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] A. Keating,et al. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. , 2000, Journal of Clinical Oncology.
[32] J. Sterne,et al. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. , 2000, Journal of clinical epidemiology.
[33] P. Arnow,et al. Cefepime versus Ceftazidime as Empiric Therapy for Fever in Neutropenic Patients with Cancer , 2000, The Annals of pharmacotherapy.
[34] L. Elting,et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Y. Humblet,et al. Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients , 2000, Annals of Hematology.
[36] Fu-Der Wang,et al. A Comparative Study of Cefepime versus Ceftazidime as Empiric Therapy of Febrile Episodes in Neutropenic Patients , 1999, Chemotherapy.
[37] P. Biron,et al. Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer). , 1998, The Journal of antimicrobial chemotherapy.
[38] D. Cook,et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? , 1998, The Lancet.
[39] D. Hoelzer,et al. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study. , 1998, European journal of medical research.
[40] H. Senn,et al. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients , 1998, Supportive Care in Cancer.
[41] M. Territo,et al. Randomized comparison of sulbactam/cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[42] Ronald N. Jones,et al. Inducible amp C beta-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). , 1997, Diagnostic microbiology and infectious disease.
[43] J. Aparicio,et al. Randomised comparison of ceftazidime and imipenem as initial monotherapy for febrile episodes in neutropenic cancer patients. , 1996, European Journal of Cancer.
[44] M. Boogaerts,et al. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. The Meropenem Study Group of Leuven, London and Nijmegen. , 1995, The Journal of antimicrobial chemotherapy.
[45] R. J. Hayes,et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.
[46] C. Sanders. Cefepime: the next generation? , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[47] L. Young,et al. Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Infectious Diseases Society of America and the Food and Drug Administration. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[48] E. Anaissie,et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. , 1992, Archives of internal medicine.
[49] T. Chan,et al. Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients , 1990, Antimicrobial Agents and Chemotherapy.
[50] E. Anaissie,et al. Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients. , 1988, The American journal of medicine.
[51] L. Elting,et al. Escherichia coli bacteremia in cancer patients. , 1986, The American journal of medicine.
[52] V. Melikian,et al. Treatment of Febrile Episodes in Neutropenic Patients , 1976, Scottish medical journal.
[53] G. Bodey,et al. Comment on: empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. , 2006, Journal of Antimicrobial Chemotherapy.
[54] R. Masterton,et al. Trends in antimicrobial susceptibility in UK centres: the MYSTIC Programme (1997-2002). , 2006, International journal of antimicrobial agents.
[55] A. Glasmacher,et al. An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[56] G. Jacoby,et al. The New b -Lactamases , 2005 .
[57] G. Bodey,et al. Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients , 2005, European Journal of Clinical Microbiology and Infectious Diseases.
[58] Ronald N. Jones,et al. Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000). , 2003, International journal of antimicrobial agents.
[59] Á. Figuera,et al. Initial empiric therapy of febrile neutropenia with antibiotic monotherapy. Piperacillin/tazobactam versus imipenem/cilastatin (1994-1996) , 2001 .
[60] Douglas G. Altman,et al. Systematic Reviews in Health Care , 2001 .
[61] P. Johansson,et al. Empiric monotherapy for febrile neutropenia--a randomized study comparing meropenem with ceftazidime. , 1998, Scandinavian journal of infectious diseases.
[62] P. Biron. Cefepime versus imipenem-cilastin as empirical monotherapy in 400 febrile patients with short duration neutropenia , 1998 .
[63] Igor Sartori,et al. Empirical Evidence of Bias. Dimensions of Methodological Quality Associated with Estimates of Treatment Effects in Controlled Trials , 1996 .
[64] S. Steinberg,et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] E. Anaissie,et al. Beta-lactam regimens for the febrile neutropenic patient. , 1990, Cancer.
[66] E. Anaissie,et al. β‐Lactam regimens for the febrile neutropenic patient , 1990 .